Viatris posts 2024 net loss of $634 million; 2025 guidance includes Indore impact
On February 27, 2025, Viatris reported fourth quarter and full-year 2024 results and issued 2025 guidance. Full-year 2024 total revenues were $14.7 billion, down 5% as reported, and the U.S. GAAP net loss was $634.2 million, compared with net earnings of $54.7 million in 2023. The company guided 2025 total revenues to $13.5 billion to $14.0 billion and adjusted EPS to $2.12 to $2.26, and said an FDA import alert at its Indore facility is expected to reduce 2025 total revenues by about $500 million and adjusted EBITDA by about $385 million.
Key points
- Full-year 2024 total revenues were $14.7 billion, down 5% as reported; adjusted EPS was $2.65, versus $2.93 in 2023.
- U.S. GAAP net loss was $(634.2) million for 2024, compared with net earnings of $54.7 million in 2023.
- 2025 guidance: total revenues of $13.5 billion to $14.0 billion and adjusted EPS of $2.12 to $2.26.
- Indore facility impact is estimated at about $500 million to 2025 total revenues and about $385 million to adjusted EBITDA; the company plans $500 million to $650 million in 2025 share repurchases.
The filing
Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 27, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.